RWD and RWE are not the same: FDA leaders dispel common misconceptions in new papernews2023-10-20T19:15:12+00:00October 20th, 2023|Endpoints News|
Nectar Lifesciences hit with untitled letter over repeat GMP issues at antimicrobial sitenews2023-10-20T17:40:22+00:00October 20th, 2023|Endpoints News|
Eli Lilly cracks down on importers and distributors of compounded Mounjaronews2023-10-20T16:43:39+00:00October 20th, 2023|Endpoints News|
GSK doles out $85M upfront to license Hansoh Pharma’s antibody-drug conjugate for gynecologic cancers news2023-10-20T15:48:38+00:00October 20th, 2023|Endpoints News|
French biotech Abivax makes Nasdaq debut, aiming to raise $236M to get PhIII data in IBDnews2023-10-20T15:07:28+00:00October 20th, 2023|Endpoints News|
Biogen CEO Chris Viehbacher: Immunology is a natural fit at biotech, calls for ‘reinvention’news2023-10-20T14:53:13+00:00October 20th, 2023|Endpoints News|
Keytruda’s cervical cancer data; Arcutis’ offering; Alaya.bio announces a CAR-T dealnews2023-10-20T14:44:06+00:00October 20th, 2023|Endpoints News|
Updated: Amgen spotlights new efficacy, safety data of mid-phase tarlatamab trial in hard-to-treat cancer: #ESMO23news2023-10-20T14:42:43+00:00October 20th, 2023|Endpoints News|
J&J unveils PhIIa data of oral antiviral that aims to prevent dengue fevernews2023-10-20T14:23:59+00:00October 20th, 2023|Endpoints News|
#ESMO23 dispatch: What to know about patritumab deruxtecan, the HER3 ADC that got Merck to pay $2B cashnews2023-10-20T11:14:30+00:00October 20th, 2023|Endpoints News|
